Which donor or graft source should you choose for the strongest GVL? Is there really any difference

被引:6
|
作者
Weisdorf, Daniel [1 ]
机构
[1] Univ Minnesota, Adult Blood & Marrow Transplant Program, Minneapolis, MN 55455 USA
关键词
bone marrow; graft source; GVL; graft-versus-leukemia; haploidentical; HCT; hematopoietic cell transplantation; HLA-matched donors; peripheral blood; relapse; UCB; umbilical cord blood; UMBILICAL-CORD BLOOD; HEMATOPOIETIC-CELL TRANSPLANTATION; UNRELATED DONOR; BONE-MARROW; ACUTE-LEUKEMIA; POSTTRANSPLANTATION CYCLOPHOSPHAMIDE; STEM-CELLS; OUTCOMES; ADULTS; RECIPIENTS;
D O I
10.1016/j.beha.2013.10.010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Patients undergoing allogeneic hematopoietic cell transplantation (HCT) face relapse of their malignancy as the most frequent cause of treatment failure. It has been postulated that the allogeneic neoplastic potency of different donor or graft sources may differ and in some situations, a particular graft source might be preferred. Data on this supposition has been reviewed here to consider HLA-matched siblings, HLA-matched or partially matched unrelated donors (URD), unrelated umbilical cord blood (UCB), and haploidentical as well as blood or marrow grafts. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码:293 / 296
页数:4
相关论文
共 28 条